Kalamazoo, Mich.-based Ablative Solutions Inc. is looking to make a mark in the hypertension space. To that end, it has reported the first close of its $77 million series D funding round to back the completion of clinical trials for U.S. and European regulatory submissions for its renal denervation technology. Read More
